Intended Cooperation
ions.bio seeks to expand its presence in the United States through direct collaboration with biotech and pharmaceutical companies, as well as partnerships with leading research institutions. The company aims to establish project-based collaborations and long-term relationships focused on biomarker discovery, drug development support, and data generation. In addition, ions.bio is interested in engaging with venture capital firms, incubators, and ecosystem partners to access high-potential biotech portfolios and scale its market reach.
Products/Services
ions.bio delivers a fully integrated, end-to-end proteomics and multi-omics platform covering sample sourcing, data generation, and AI-driven data analysis.
- Biomarker discovery and validation for diagnostics and therapeutic development
- Advanced proteomics and multi-omics data generation (mass spectrometry-based)
- AI-powered bioinformatics analysis and interactive data interpretation platform
- Drug target identification and mechanism-of-action (MoA) studies
ions.bio GmbH is a Germany-based biotechnology company providing end-to-end proteomics solutions for drug discovery, biomarker development, and translational research.
The company integrates biosample sourcing, high-throughput mass spectrometry, and advanced bioinformatics into a unified platform that transforms biological questions into actionable insights. With extensive scientific expertise and a strong track record in large-scale data generation, ions.bio serves biotech, pharma, AI, and academic partners globally.
- Dr. Fabian Hosp
- hosp@ions.bio
- https://ions.bio
Arrange an appointment for an
initial consultation
Are you interested in one of our projects? Then book a consultation now. We will be happy to present the project to you.
Philip Okito
General Manager and Co-Founder
- service@traide.de
- + 4922193544511
- Hohenstaufenring 42, 50674 Köln
free of charge & without obligation